论文部分内容阅读
目的观察吉西他滨联合卡铂方案治疗晚期复治鼻咽癌的疗效及毒性反应。方法34例均为一线含顺铂方案化疗失败的晚期鼻咽癌患者,给予吉西他滨与卡铂治疗,吉西他滨1000mg/m2,静脉滴注,第1、8天;卡铂AUC5,静脉滴注,第2天,21d为1周期,每例患者治疗2周期以上。结果全组完全缓解4例,部分缓解17例,稳定8例,进展5例,总有效率为61.8%。中位生存期8.3个月,1年生存率为43.8%。最常见的毒副反应为骨髓抑制,Ⅲ～Ⅳ度白细胞和血小板下降发生率分别为35.3%和23.6%,其余毒副反应均轻微,可耐受。结论吉西他滨联合卡铂方案对一线含顺铂方案化疗失败的晚期鼻咽癌有较好的疗效,毒性反应可以耐受。
Objective To observe the curative effect and toxicity of gemcitabine combined with carboplatin in the treatment of advanced nasopharyngeal carcinoma. Methods Thirty-four patients were treated with gemcitabine and carboplatin. The patients were treated with gemcitabine and 1000 mg / m2 gemcitabine intravenously. On day 1,8, carboplatin AUC5, intravenous drip, 2 days, 21d for 1 cycle, each patient treated for more than 2 cycles. Results The whole group was completely relieved in 4 cases, partially relieved in 17 cases, stabilized in 8 cases, and progressed in 5 cases. The total effective rate was 61.8%. The median survival time was 8.3 months, and the 1-year survival rate was 43.8%. The most common side effects were myelosuppression. The incidences of grade Ⅲ ~ Ⅳ leukopenia and thrombocytopenia were 35.3% and 23.6%, respectively. The remaining toxicities were mild and tolerable. Conclusion The combination of gemcitabine and carboplatin has a good curative effect on advanced nasopharyngeal carcinoma which failed to receive cisplatin chemotherapy.